¼¼°èÀÇ ¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ(PNH) ¹× ºñÀüÇü ¿ëÇ÷¼º ¿äµ¶ÁõÈıº(aHUS) ½ÃÀå º¸°í¼­(2025³â)
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025
»óǰÄÚµå : 1760671
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,217,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,987,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,756,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ(PNH) ¹× ºñÀüÇü ¿ëÇ÷¼º ¿äµ¶ÁõÈıº(aHUS) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ½ÂÀÎÀÇ Áõ°¡, »ý¸í °øÇÐ ±â¾÷°ú ¿¬±¸ ±â°ü °£ÀÇ Çù·Â °­È­, °³ÀÎ ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Èñ±Í Áúȯ ½Å»ý ±â¾÷¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÀÓ»ó ½ÃÇè ¹× ¿¬±¸ÀÇ Áõ°¡¿Í °°Àº ¿äÀο¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â º¸Ã¼ ¾ïÁ¦ ¿ä¹ýÀÇ ¹ßÀü, À¯ÀüÀÚ Ä¡·á Á¢±Ù¹ýÀÇ ÅëÇÕ, °³ÀÎ ¸ÂÃãÇü ÀǾàǰÀÇ ¹ßÀü, ±â¼ú Á᫐ Áø´Ü µµ±¸, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀ» À§ÇÑ ±â¼úÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù.

Èñ±Í ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ(PNH) ¹× ºñÀüÇü ¿ëÇ÷¼º ¿äµ¶ÁõÈıº(aHUS) ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Èñ±Í ÁúȯÀº Àα¸ÀÇ ¼Ò¼ö, ÀϹÝÀûÀ¸·Î 20¸¸ ¸í ¹Ì¸¸¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÇÇÐÀû »óÅ·Î, º¹À⼺, ÁßÁõµµ ¹× Àü¹®ÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÑ °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Èñ±Í ÁúȯÀÇ Áõ°¡ Ãß¼¼´Â Áø´Ü ±â¼úÀÇ ¹ßÀü¿¡ ±âÀÎÇϸç, ÀÌ´Â ÀÌÀü¿¡ º¸°íµÇÁö ¾Ê¾Ò°Å³ª Áø´ÜµÇÁö ¾ÊÀº ÁúȯÀÇ Å½Áö ¹× ½Äº°À» °³¼±Çß½À´Ï´Ù. PNH¿Í aHUS´Â Ä¡·á ¿É¼ÇÀÌ Á¦ÇÑÀûÀÎ ÁúȯÀÇ º´¸®»ý¸®ÇÐ ¹× ÀáÀçÀû Ä¡·á Ç¥Àû¿¡ ´ëÇÑ ÅëÂûÀ» Á¦°øÇÔÀ¸·Î½á Èñ±Í ÁúȯÀÇ ÀÌÇØ¿Í Ä¡·á¿¡ ±â¿©ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 11¿ù, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ¹Ì±¹¿¡¼­ 7,000°³ ÀÌ»óÀÇ Èñ±Í ÁúȯÀÌ 3,000¸¸ ¸í ÀÌ»óÀÇ »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù. ±× °á°ú, Èñ±Í ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 PNH ¹× aHUS ºÎ¹®ÀÇ ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

PNH ¹× aHUS ½ÃÀåÀÇ ¼±µµ ±â¾÷µéÀº Ä¡·á È¿°ú Çâ»ó°ú ȯÀÚ ÆíÀǼºÀ» À§ÇØ º¸Ã¼ ¾ïÁ¦Á¦¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. º¸Ã¼ ¾ïÁ¦Á¦´Â º´¿øÃ¼¿Í ¼Õ»óµÈ ¼¼Æ÷¸¦ Á¦°ÅÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â º¸Ã¼ ½Ã½ºÅÛÀÇ Æ¯Á¤ ¼ººÐÀ» Â÷´ÜÇÏ´Â Ä¡·áÁ¦ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 12¿ù, ½ºÀ§½º¿¡ º»»ç¸¦ µÐ Á¦¾à ȸ»çÀÎ Novartis AG´Â ¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ ¼ºÀΠȯÀÚ¸¦ À§ÇÑ ÃÖÃÊÀÇ °æ±¸¿ë ´ÜÀÏ ¿ä¹ýÁ¦ÀÎ Fabhalta(iptacopan)¿¡ ´ëÇØ FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. Fabhalta´Â ¼öÇ÷ ¾øÀ̵µ ¿ì¼öÇÑ Çì¸ð±Û·Îºó °³¼± È¿°ú¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ º¸Ã¼ ¾ïÁ¦Á¦´Â ´ëü º¸Ã¼ °æ·ÎÀÇ ÀÎÀÚ B¸¦ ¾ïÁ¦ÇÏ¿© Ç÷°ü ³» ¹× Ç÷°ü ¿Ü ¿ëÇ÷À» È¿°úÀûÀ¸·Î Á¦¾îÇÕ´Ï´Ù. °æ±¸ Åõ¿©·Î Áúº´ °ü¸®°¡ °£´ÜÇØÁö°í ȯÀÚÀÇ »îÀÇ ÁúÀÌ Çâ»óµÇ¸ç, ÀæÀº ÁÖÀÔÀÇ ºÎ´ãÀÌ »ç¶óÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª 19 ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are rare, life-threatening blood disorders caused by the uncontrolled activation of the complement system, a component of the immune system. PNH results in the destruction of red blood cells, while aHUS leads to the formation of blood clots in small blood vessels, primarily affecting the kidneys and other vital organs.

The main treatments for PNH and aHUS include Soliris and Ultomiris. Soliris, also known by its generic name eculizumab, is a monoclonal antibody medication used to treat these rare blood disorders. The treatment options for these conditions include complement inhibitors, plasma exchange or infusion, and others. Diagnostic methods involve clinical diagnosis, genetic testing, and biomarker testing. These treatments and diagnostic methods are used by various end-users, including hospitals, specialty clinics, research institutes, and more.

The paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market research report is one of a series of new reports from The Business Research Company that provides paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market statistics, including the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) industry's global market size, regional shares, competitors with the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market share, detailed paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market segments, market trends and opportunities, and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market. This paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market size has grown strongly in recent years. It will grow from $5.57 billion in 2024 to $5.99 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to factors such as the increasing prevalence of PNH and aHUS, rising investment in rare disease research, growing demand for targeted therapies, increased awareness of PNH and aHUS, and the growing adoption of complement inhibitors.

The paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market size is expected to see strong growth in the next few years. It will grow to $7.93 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecast period can be attributed to factors such as increasing regulatory approvals for new treatments, growing collaboration between biotech companies and research institutes, rising demand for personalized medicine, increasing investment in rare disease startups, and a growing number of clinical trials and research studies. Key trends in the forecast period include advancements in complement inhibition therapies, the integration of gene therapy approaches, developments in personalized medicine, technology-driven diagnostic tools, and the integration of technology for remote patient monitoring.

The growing prevalence of rare diseases is expected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market. Rare diseases are medical conditions that affect a small percentage of the population, typically fewer than 200,000 individuals, and are often characterized by their complexity, severity, and the need for specialized treatment. The rise in rare diseases can be attributed to advances in diagnostic technologies, which have improved the detection and identification of previously underreported or undiagnosed conditions. PNH and aHUS contribute to a deeper understanding and treatment of rare diseases by providing insights into their pathophysiology and potential therapeutic targets for conditions with limited treatment options. For example, in November 2024, the Food and Drug Administration (FDA) reported that over 7,000 rare diseases affected more than 30 million individuals in the United States. As a result, the increasing prevalence of rare diseases is driving market growth in the PNH and aHUS sectors.

Leading companies in the PNH and aHUS market are focusing on the development of innovative therapies, such as complement inhibitors, to enhance treatment outcomes and patient convenience. Complement inhibitors are therapeutic agents that block specific components of the complement system, which plays a role in clearing pathogens and damaged cells. For example, in December 2023, Novartis AG, a pharmaceutical company based in Switzerland, received FDA approval for Fabhalta (iptacopan), the first oral monotherapy for treating adults with paroxysmal nocturnal hemoglobinuria. Fabhalta offers superior hemoglobin improvement without the need for transfusions. This innovative complement inhibitor works by inhibiting Factor B in the alternative complement pathway, effectively controlling both intravascular and extravascular hemolysis. Its oral administration simplifies disease management and improves the quality of life for patients, eliminating the burden of frequent infusions.

In January 2025, Samsung Bioepis Co. Ltd., a biopharmaceutical company based in South Korea, partnered with Teva Pharmaceutical Industries Ltd. to develop and commercialize Soliris (eculizumab) biosimilars, including EPYSQLI (eculizumab-aagh), for rare diseases. This collaboration aims to improve access to affordable treatment options for U.S. patients. Teva, an Israeli pharmaceutical company, specializes in the development, manufacturing, and commercialization of medicines for various rare diseases, including PNH and aHUS.

Major players in the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market are Roche Holding AG, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Alexion Pharmaceuticals Inc., UCB Pharma Limited, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Genentech Inc., Omeros Corporation, CinnaGen Co., Apellis Pharmaceuticals Inc., CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, NovelMed Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Akari Therapeutics plc.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market consists of revenues earned by entities by providing services such as bone marrow biopsy, flow cytometry testing, and multidisciplinary care coordination. The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market also includes sales of flow cytometry reagents, anticoagulants, and pegcetacoplan. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Characteristics

3. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Trends And Strategies

4. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Growth Analysis And Strategic Analysis Framework

6. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Segmentation

7. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Regional And Country Analysis

8. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

9. China Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

10. India Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

12. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

13. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

14. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

15. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

16. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

17. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

18. France Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

19. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

20. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

21. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

22. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

23. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

24. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

25. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

26. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

27. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

28. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

29. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

30. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Competitive Landscape And Company Profiles

31. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Other Major And Innovative Companies

32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

34. Recent Developments In The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market

35. Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â